Choudhary Narendra S, Saigal Sanjiv, Bansal Rinkesh K, Saraf Neeraj, Gautam Dheeraj, Soin Arvinder S
Institute of Liver Transplantation and Regenerative Medicine, Medanta The Medicity, Gurugram, India.
Department of Pathology, Medanta The Medicity, Gurugram, India.
J Clin Exp Hepatol. 2017 Dec;7(4):358-366. doi: 10.1016/j.jceh.2017.10.003. Epub 2017 Nov 7.
While antibody mediated hyper-acute vasculitic rejection is rare in liver transplant recipients, acute and chronic rejection have clinical significance. The liver allograft behaves differently to other solid organ transplants as acute rejection generally does not impair graft survival and chronic rejection (CR) is uncommon. The incidence of acute and chronic rejection has declined in current era due to improved immunosuppressive regimens. Acute rejection generally improves with steroid boluses and steroid resistant rejection is uncommon. CR may improve with escalation of immunosuppression or may result in irreversible loss of graft function leading to retransplantation or death. The current review discusses diagnosis and management of acute and chronic liver allograft rejection.
虽然抗体介导的超急性血管性排斥反应在肝移植受者中很少见,但急性和慢性排斥反应具有临床意义。肝移植受者的肝脏移植物与其他实体器官移植表现不同,因为急性排斥反应通常不会损害移植物存活,而慢性排斥反应并不常见。由于免疫抑制方案的改进,当前时代急性和慢性排斥反应的发生率有所下降。急性排斥反应通常通过大剂量类固醇治疗而改善,对类固醇耐药的排斥反应并不常见。慢性排斥反应可能随着免疫抑制的升级而改善,也可能导致移植物功能不可逆转的丧失,从而导致再次移植或死亡。本综述讨论了肝移植急性和慢性排斥反应的诊断和管理。